January 21, 2021 -- Kuur Therapeutics has released results from phase I clinical trials evaluating its off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT)-cell immunotherapy candidates in relapsed/refractory (R/R) neuroblastoma and R/R CD19-positive malignancies.
In the GinaKit2 study of KUR-501 (autologous GD2 CAR-NKT cells) in patients with R/R neuroblastoma, the company observed one complete result in ten patients, and tumor biopsies showed CAR-NKT cells homing to the neuroblastoma tumor site at all dose levels. The candidate has so far demonstrated a promising safety profile. In the Anchor study of KUR-502 (off-the-shelf CD19 CAR-NKT cells) in patients with R/R CD19-positive malignancies, two patients have been treated with either complete or partial responses.
The trials are being conducted at Baylor College of Medicine (Kuur's CAR-NKT cell platform partner), Houston Methodist Hospital, and Texas Children's Hospital.
Copyright © 2021 scienceboard.net